SCHEMBL10189779

SCHEMBL10189779

Cc1cc(-c2nn[nH]c2-c2ccc(O)cc2)cc2c1OCO2

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 3/20 0.34
MAP2K4 P45985 1/20 0.34
MAPKAPK2 P49137 1/20 0.34
MAPKAPK3 Q16644 1/20 0.34
MAPK6 Q16659 1/20 0.34
MAPKAPK5 Q8IW41 1/20 0.34
UGT1A1 P22309 1/20 0.34
UGT1A8 Q9HAW9 1/20 0.34
MAPT P10636 7/20 0.34
KDM4E B2RXH2 6/20 0.34
MEN1 O00255 5/20 0.34
KMT2A Q03164 5/20 0.34
ALDH1A1 P00352 5/20 0.34
LMNA P02545 4/20 0.34
HPGD P15428 4/20 0.34
NPSR1 Q6W5P4 3/20 0.34
HTT P42858 3/20 0.34
TDP1 Q9NUW8 2/20 0.34
POLB P06746 1/20 0.34
HSP90AA1 P07900 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10189782 0.86 ALDH1A1 (0.35) MAPK1MAP2K4MAPKAPK2MAPKAPK3MAPK6
SCHEMBL10189775 0.86 MAPT (0.34) MAPK1MAP2K4MAPKAPK2MAPKAPK3MAPK6
SCHEMBL3304242 0.85 ALDH1A1 (0.49) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL10189780 0.83 MEN1 (0.36) MAPK1MAP2K4MAPKAPK2MAPKAPK3MAPK6
SCHEMBL10189784 0.82 ALDH1A1 (0.33) MAPK1MAP2K4MAPKAPK2MAPKAPK3MAPK6
SCHEMBL10189758 0.82 PTGS2 (0.31) MAPK1MAP2K4MAPKAPK2MAPKAPK3MAPK6
SCHEMBL10189778 0.82 BRD4 (0.32) MAPK1MAP2K4MAPKAPK2MAPKAPK3MAPK6
SCHEMBL10189765 0.82 ALOX12 (0.45) MAPK1MAPTKDM4EMEN1KMT2A
SCHEMBL10189757 0.81 MAPK1 (0.33) MAPK1MAP2K4MAPKAPK2MAPKAPK3MAPK6
SCHEMBL10189759 0.81 LMNA (0.37) MAPK1MAP2K4MAPKAPK2MAPKAPK3MAPK6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9175022-B2 Compounds for the treatment of proliferative disorders SYNTA PHARMACEUTICALS CORP. (US) 2015-11-03 US disclosed
US-8501790-B2 Compounds for the treatment of proliferative disorders SYNTA PHARMACEUTICALS CORP. (US) 2013-08-06 US disclosed
US-20120022118-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS SYNTA PHARMACEUTICALS CORP. 2012-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022118-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS RB1, MKI67, MAPRE1 MAPK1 750/4885MAP2K4 1560/4885MAPKAPK2 1068/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.